TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14691434

Group type: EXPERIMENTAL
Intervention: Echocardiographic measures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical predictor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters
Number of subjects: 100
Study: 11789646

Group type: EXPERIMENTAL
Intervention: Various interventions in prehospital trauma care
Number of subjects: 6806

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6806
Study: 11907931

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and 5 mg medroxyprogesterone acetate (MPA) for 2 years
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-users of HRT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic women
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normocholesterolemic women
Number of subjects: 72
Study: 7815242

Group type: EXPERIMENTAL
Intervention: High dosing (1,500 U lipase/kg body weight/meal, 750 U lipase/kg body weight/snack)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard dosing (500 U lipase/kg body weight/meal, 250 U lipase/kg body weight/snack)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High dosing in Group 1 (n = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High dosing in Group 2 (n = 14)
Number of subjects: 21
Study: 2900252

Group type: EXPERIMENTAL
Intervention: Bethanechol (5.0 mg s.c.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine (1.0 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bethanechol with islet clamp technique
Number of subjects: 0
Study: 30851397

Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 124
Study: 31197369

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) treatment sessions for quadriceps muscles over 16 weeks (36 sessions)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NMES training intensity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Minimum NMES training intensity
Number of subjects: 24
Study: 28277689

Group type: EXPERIMENTAL
Intervention: Relationship skills education
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Control group (no relationship skills education)
Number of subjects: 2540
Study: 25461495

Group type: EXPERIMENTAL
Intervention: Enhanced protein weight reduction (Protein) arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional weight loss (Control) arm
Number of subjects: 0
Study: 23218533

Group type: EXPERIMENTAL
Intervention: Sublingual Zolpidem 10mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sublingual Zolpidem 5mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral Zolpidem 10mg
Number of subjects: 58
Study: 16574034

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) 35 mug/h patch
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transdermal fentanyl (DDTDF) 25 mug/h patch
Number of subjects: 46
Study: 12811569

Group type: EXPERIMENTAL
Intervention: Slow relaxation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fast relaxation
Number of subjects: 22
Study: 9895016

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8724889

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 585

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 585

Group type: COMPARATOR
Intervention: Usual blood pressure goal
Number of subjects: 585
Study: 1793781

Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg t.d.s., by rectal administration
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 6404471

Group type: EXPERIMENTAL
Intervention: Infrared coagulation (n=66)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Rubber band ligation (n=71)
Number of subjects: 137
Study: 31101487

Group type: EXPERIMENTAL
Intervention: Edetate disodium-based chelation
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 162
Study: 27654854

Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 26466871

Group type: EXPERIMENTAL
Intervention: Tasimelteon (20 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 23642492

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sulthiame (STM)
Number of subjects: 44
Study: 21729932

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard Policy (SP)
Number of subjects: 175
Study: 20491142

Group type: EXPERIMENTAL
Intervention: HyperHAES solution (7.2% sodium chloride and hydroxyethyl starch 200/0.5)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 15% mannitol solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10% sodium chloride solution
Number of subjects: 25
Study: 17340596

Group type: EXPERIMENTAL
Intervention: Caries preventive agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilevel logistic regression modelling
Number of subjects: 0
Study: 15633327

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11719739

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g) plus intravenous metoclopramide (20 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (20 mg) plus placebo (intravenous saline solution)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate plus metoclopramide
Number of subjects: 44
Study: 9167373

Group type: EXPERIMENTAL
Intervention: buprenorphine 0.2 mg sublingually two hours before dilatation
Number of subjects: 31

Group type: COMPARATOR
Intervention: pentazocine 30 mg intravenously five minutes before dilatation
Number of subjects: 31
Study: 7701413

Group type: EXPERIMENTAL
Intervention: Rehabilitative therapy (FKT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: FKT and Ditropan (1 tablet 3 times daily for weeks therapy)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Traditional therapy with electric functional stimulation (SEF)
Number of subjects: 121
Study: 3295180

Group type: EXPERIMENTAL
Intervention: Fenoterol depot (21 mg, single dose, p.o.)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fenoterol (22.5 mg, three doses, p.o.)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fenoterol depot
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 131
Study: 31727402

Group type: EXPERIMENTAL
Intervention: Supine position using a fracture table
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine/sloppy lateral positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct lateral positioning with leg free draped
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral positioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interest in randomized control trial comparing lateral positioning vs. supine with traction
Number of subjects: 0
Study: 29316341

Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention during phase I
Number of subjects: 636

Group type: COMPARATOR
Intervention: Wait-list control group (received intervention during phase II)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Phase I intervention sites
Number of subjects: 636
Study: 29262472

Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 40
Study: 26118944

Group type: EXPERIMENTAL
Intervention: 6-week duration of anticoagulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-month duration of anticoagulation
Number of subjects: 100
Study: 23597217

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite (NaOCl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20% Formocresol (FC)
Number of subjects: 24
Study: 21185153

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 21
Study: 19630704

Group type: EXPERIMENTAL
Intervention: Heavy drinking (intoxication)
Number of subjects: 0
Study: 16563590

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15344464

Group type: EXPERIMENTAL
Intervention: Knowledge-driven automated extraction method
Number of subjects: 30
Study: 10858971

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 300

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 300
Study: 9382121

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 mg alendronate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 mg alendronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1313762

Group type: EXPERIMENTAL
Intervention: 15 g/day rice bran
Number of subjects: 18

Group type: COMPARATOR
Intervention: 15 g/day wheat bran
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 g/day rice bran
Number of subjects: 18

Group type: COMPARATOR
Intervention: 15 g wheat bran
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 g rice bran
Number of subjects: 18
Study: 3933199

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nightly for 3 years
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nightly
Number of subjects: 1726
Study: 31348430

Group type: EXPERIMENTAL
Intervention: 5-hour exposure to brazing fumes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3-hour exposure to brazing fumes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-hour exposure to brazing fumes
Number of subjects: 15
Study: 30020088

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg orally 1 hour before surgery and at postoperative 12th and 24th hours
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg orally 1 hour before surgery, placebo at postoperative 12th hour, and duloxetine 60 mg at 24th hour
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo capsules orally at all timepoints
Number of subjects: 94
Study: 26706908

Group type: EXPERIMENTAL
Intervention: Viewing e-cigarette advertisements
Number of subjects: 5020

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5020
Study: 24581401

Group type: EXPERIMENTAL
Intervention: Weighted vest
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (no weighted vest)
Number of subjects: 110
Study: 22155172

Group type: EXPERIMENTAL
Intervention: 800 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: 400 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: 1200 mg rifaximin-EIR, given twice daily for 12 weeks
Number of subjects: 402
Study: 19648021

Group type: EXPERIMENTAL
Intervention: Periosteum-polymer complex
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ilium
Number of subjects: 3
Study: 16942923

Group type: EXPERIMENTAL
Intervention: Intensive training using the compact Erlangen Active Simulator for Interventional Endoscopy-simulator
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study: 16288372

Group type: EXPERIMENTAL
Intervention: OPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior vaccination with OPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two doses of IPV
Number of subjects: 0
Study: 12162817

Group type: EXPERIMENTAL
Intervention: tgAAVCF (100,000 replication units)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study: 10609245

Group type: EXPERIMENTAL
Intervention: Topically applied 5% phenylephrine and 1% cyclopentolate with digital compression by patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topically applied 5% phenylephrine and 1% cyclopentolate with digital compression by investigators
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intraoperative injection of epinephrine 1:25,000 in the anterior chamber
Number of subjects: 75
Study: 7718375

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose isoflurane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between SNP and isoflurane
Number of subjects: 10
Study: 2248029

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid 300 mg, twice a day for seven consecutive days
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo, twice a day for seven consecutive days
Number of subjects: 40
Study: 7221983

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (7 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mustine (20 mg)
Number of subjects: 21
Study: 29688123

Group type: EXPERIMENTAL
Intervention: Early endovenous ablation of superficial venous reflux with compression therapy
Number of subjects: 450

Group type: COMPARATOR
Intervention: Deferred endovenous ablation of superficial venous reflux with compression therapy
Number of subjects: 450
Study: 28351379

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg) for 3 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Partial endodontic treatment
Number of subjects: 120
Study: 25581605

Group type: EXPERIMENTAL
Intervention: Routine incontinence care plus the suspension positioning system (SPS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine FI nursing care (control group)
Number of subjects: 200
Study: 23988341

Group type: EXPERIMENTAL
Intervention: PVI with CFE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CFE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All ablation strategies
Number of subjects: 100
Study: 21110172

Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) high dose (six capsules, thrice a day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) low dose (four capsules, thrice a day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablets (four tablets, thrice a day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) high dose
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Composite sophora colon-soluble capsules (CSCC) low dose
Number of subjects: 126

Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablets
Number of subjects: 126
Study: 18203047

Group type: EXPERIMENTAL
Intervention: Psychoeducational program (PEP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intervention (Control Group 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Total population (both groups)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 16299017

Group type: EXPERIMENTAL
Intervention: Short-term normobaric hypoxia (simulating 3636 m altitude, inspired O2=13%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 12
Study: 11965231

Group type: EXPERIMENTAL
Intervention: Radioimmunoconjugates emitting beta-particles (e.g., 131I-anti-CD33, 90Y-anti-CD33, 131I-anti-CD45, 188Re-anti-CD66c)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioimmunoconjugates emitting alpha-particles (e.g., 213Bi-anti-CD33)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiolabeled antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiolabeled antibodies used in conjunction with conditioning regimens
Number of subjects: 0
Study: 9829785

Group type: EXPERIMENTAL
Intervention: Shock exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associative shock conditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpleasant pictures
Number of subjects: 0
Study: 7926293

Group type: EXPERIMENTAL
Intervention: GAD‐absorbable ICAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD‐nonabsorbable ICAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low positive levels of GAAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of GAAs (1,800 cpm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD autoantibodies (GAAs)
Number of subjects: 0
Study: 2679680

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin (1 g:2 g) administered intravenously every 8 h
Number of subjects: 95

Group type: COMPARATOR
Intervention: cefotetan (2 g) administered intravenously every 12 h
Number of subjects: 95
Study: 19548446

Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXT)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Alprostadil
Number of subjects: 260
Study: 428840

Group type: EXPERIMENTAL
Intervention: Actihaemyl (6 weeks, twice weekly 10 ml i.v.)
Number of subjects: 32
Study: 30741761

Group type: EXPERIMENTAL
Intervention: Ergonomic latex pillow
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine physical therapy alone (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ergonomic latex pillow with physical therapy
Number of subjects: 42
Study: 29514682

Group type: EXPERIMENTAL
Intervention: Support workers delivering interventions to older people
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual general practice care
Number of subjects: 100
Study: 27762190

Group type: EXPERIMENTAL
Intervention: MTX+Pred
Number of subjects: 134

Group type: COMPARATOR
Intervention: MTX+Plac
Number of subjects: 134
Study: 25726209

Group type: EXPERIMENTAL
Intervention: Active group (hygienic‐dietary recommendations on diet, exercise, sleep, and sun exposure)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Active group (hygienic‐dietary recommendations)
Number of subjects: 77
Study: 22825573

Group type: EXPERIMENTAL
Intervention: Stopwatch urine stream interruption test (UST)
Number of subjects: 47
Study: 19387233

Group type: EXPERIMENTAL
Intervention: Paragon CRT reverse geometry rigid gas permeable contact lenses (-2.00 diopters)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paragon CRT reverse geometry rigid gas permeable contact lenses (-4.00 diopters)
Number of subjects: 14
Study: 17896170

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 31
Study: 15149710

Group type: EXPERIMENTAL
Intervention: Self-report depressive symptoms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Parent-report anxiety symptoms
Number of subjects: 2
Study: 12197896

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 7
Study: 9862576

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg m(‐2) on day 1 (112 patients)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg m(‐2) on day 1 (111 patients)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg m(‐2) on days 1, 2, and 3 (111 patients)
Number of subjects: 334
Study: 7623523

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at low doses (30 mg and 100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at moderate doses (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) renal clearance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salicyluric acid (SUA) renal clearance
Number of subjects: 12
Study: 2507152

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hexabrix 250
Number of subjects: 0
Study: 67128

Group type: EXPERIMENTAL
Intervention: Rectal oxymorphone
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intramuscular oxymorphone
Number of subjects: 136
Study: 31822298

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 27618386

Group type: EXPERIMENTAL
Intervention: VL15 (15% velocity loss)
Number of subjects: 16

Group type: COMPARATOR
Intervention: VL30 (30% velocity loss)
Number of subjects: 16
Study: 26253566

Group type: EXPERIMENTAL
Intervention: Initial dual therapy (combination therapy)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 536
Study: 24113771

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 12
Study: 21857356

Group type: EXPERIMENTAL
Intervention: CD4 result at time of HIV diagnosis
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard of care (CD4 collection after 1 week)
Number of subjects: 344
Study: 17822582

Group type: EXPERIMENTAL
Intervention: CT instruction in civic education (experimental group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No CT programme (control group)
Number of subjects: 68
Study: 16879829

Group type: EXPERIMENTAL
Intervention: 1.35 g EPA/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.7 g EPA/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 4.05 g EPA/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EPA (all doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Highest dose of EPA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Increased EPA (all doses)
Number of subjects: 100
Study: 15043766

Group type: EXPERIMENTAL
Intervention: Supraorbital keyhole approach using eyebrow incisions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional subfrontal approach
Number of subjects: 54
Study: 11386610

Group type: EXPERIMENTAL
Intervention: Single 10‐mg dose of diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug abusers starting a prison sentence
Number of subjects: 0